Both in Biotechnology
Vir Biotechnology vs Hemab Therapeutics Holdings
Over the past year VIR returned +3.6% and COAG returned +4.5%; their daily moves had a correlation of 0.27.
VIR +3.6% COAG +4.5%Growth of $1, one year, split-adjusted
| Metric | VIR | COAG |
|---|---|---|
| Price | $11.00 | $41.18 |
| Market cap | $1.86B | $1.92B |
| Today | −2.65% | −0.65% |
| 1 month | −1.5% | +32.4% |
| 6 months | +8.1% | — |
| Year to date | +82.4% | — |
| 1 year | +85.5% | — |
| Revenue growth (YoY) | +19582.5% | — |
| Gross margin | 100.0% | — |
| Net margin | 33.5% | — |
| P/E (TTM) | — | — |
| Price / sales | 6.1× | — |
| Net cash | $532.7M | $457.5M |
| Dividend yield | — | — |
| Volatility (60d) | 51.4% | — |
| Short % of float | 12.3% | 20.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).